Pre-operative atorvastatin therapy to decrease the systemic inflammatory response after coronary artery bypass...

Area of Science:

• Cardiology
• Pharmacology
• Immunology

Background:

• Systemic inflammatory response syndrome (SIRS) is a common complication following coronary artery bypass grafting (CABG).
• Statins, like atorvastatin, possess anti-inflammatory properties that may mitigate SIRS.
• Pre-operative statin use in CABG patients warrants further investigation for its impact on inflammatory markers.

Purpose of the Study:

• To evaluate the effect of pre-operative atorvastatin on inflammatory markers and SIRS in patients undergoing elective CABG.
• To compare post-operative inflammatory responses between patients receiving pre-operative atorvastatin and those who did not.

Main Methods:

• A prospective study involving 40 patients undergoing elective CABG.
• Patients were divided into two groups: Group I (LDL cholesterol ≥ 100 mg/dL) received atorvastatin 20 mg/day for ≥ 15 days pre-operatively; Group II (LDL cholesterol < 100 mg/dL) received no antihyperlipidemic agents.
• Blood samples were collected pre-operatively and 24 hours post-operatively to measure high-sensitivity C-reactive protein (hs-CRP) and interleukin-6 (IL-6).

Main Results:

• No significant differences in demographic, pre-operative, or operative parameters between groups.
• Post-operatively, Group I showed significantly lower median hs-CRP and mean IL-6 levels compared to Group II.
• Group I patients had a shorter intensive care unit (ICU) stay, with no other significant differences in post-operative outcomes.

Conclusions:

• Pre-operative atorvastatin administration in elective CABG patients effectively reduces post-operative inflammation.
• Atorvastatin may play a role in preventing SIRS following CABG.
• Further research is recommended to confirm the clinical benefits of pre-operative statin therapy in CABG patients.